Table 1.
Baseline characteristics
| Characteristics | Overall N = 3410 |
hs-CRP ≥2.0 mg/ N = 1999 |
hs-CRP <2.0 mg/L N = 1411 |
|---|---|---|---|
|
| |||
| Demographics | |||
|
| |||
| Age | 52.1 ± 10.6 | 51.9 ± 10.4 | 52.4 ± 10.8 |
|
| |||
| Women | 1834 (53.8%) | 1170 (58.5%) | 664 (47.1%) |
|
| |||
| Race | |||
| White | 2585 (76.0%) | 1477 (74.1%) | 1108 (78.6%) |
| Black | 620 (18.2%) | 415 (20.8%) | 205 (14.5%) |
| Other | 197 (5.8%) | 101 (5.1%) | 96 (6.8%) |
|
| |||
| Socioeconomic | |||
|
| |||
| Avoids care due to cost | 1015 (30.0%) | 674 (34.1%) | 341 (24.4%) |
|
| |||
| Finances at the end of the month | |||
| Some money left over | 1277 (37.8%) | 637 (32.1%) | 640 (45.9%) |
| Just enough to make ends meet | 1214 (36.0%) | 748 (37.7%) | 466 (33.5%) |
| Not enough to make ends meet | 884 (26.2%) | 597 (30.1%) | 287 (20.6%) |
|
| |||
| Comorbidities | |||
|
| |||
| Diabetes | 969 (28.4%) | 681 (34.1%) | 288 (20.4%) |
|
| |||
| Dyslipidemia | 2096 (61.5%) | 1290 (64.5%) | 806 (57.1%) |
|
| |||
| Hypertension | 2241 (65.7%) | 1415 (70.8%) | 826 (58.5%) |
|
| |||
| Body mass index | 30.9 ± 7.1 | 32.5 ± 7.5 | 28.7 ± 5.9 |
|
| |||
| History of smoking | 2245 (65.9%) | 1424 (71.3%) | 821 (58.2%) |
|
| |||
| Prior alcohol use | 257 (7.5%) | 160 (8.0%) | 97 (6.9%) |
|
| |||
| Chronic lung disease | 320 (9.4%) | 215 (10.8%) | 105 (7.5%) |
|
| |||
| Prior myocardial infarction | 686 (20.1%) | 449 (22.5%) | 237 (16.8%) |
|
| |||
| Prior PCI | 580 (17.0%) | 362 (18.1%) | 218 (15.5%) |
|
| |||
| Atrial fibrillation | 203 (6.0%) | 119 (6.0%) | 84 (6.0%) |
|
| |||
| Stroke | 144 (4.2%) | 100 (5.0%) | 44 (3.1%) |
|
| |||
| PAD | 104 (3.1%) | 77 (3.9%) | 27 (1.9%) |
|
| |||
| STEMI at presentation | 1674 (49.1%) | 947 (47.4%) | 727 (51.5%) |
|
| |||
| Laboratory data | |||
|
| |||
| hs-CRP at 30 days | 2.6 (1.1, 6.1) | 5.2 (3.2, 9.2) | 0.9 (0.6, 1.4) |
|
| |||
| Creatinine | 1.0 ± 0.7 | 1.0 ± 0.8 | 1.0 ± 0.6 |
|
| |||
| Total cholesterol | 183.1 ± 53.4 | 186.7 ± 54.0 | 178.0 ± 52.0 |
|
| |||
| HDL-C | 40.9 ± 13.8 | 39.4 ± 12.6 | 43.2 ± 15.0 |
|
| |||
| LDL-C | 108.1 ± 39.7 | 111.3 ± 40.8 | 103.6 ± 37.6 |
|
| |||
| Triglycerides | 168.9 ± 221.8 | 180.9 ± 198.0 | 152.1 ± 250.5 |
|
| |||
| Ejection fraction | 49.7 ± 12.0 | 49.2 ± 12.4 | 50.3 ± 11.4 |
|
| |||
| Treatment characteristics | |||
|
| |||
| Revascularization | 2720 (80.5%) | 1609 (81.2%) | 1111 (79.6%) |
|
| |||
| Statin therapy at admission | 1042 (30.6%) | 643 (32.2%) | 399 (28.3%) |
|
| |||
| Lipid lowering therapy at admission | 1105 (32.4%) | 681 (34.1%) | 424 (30.0%) |
|
| |||
| Discharge medications | |||
| Statin | 3098 (92.3%) | 1820 (92.5%) | 1278 (91.9%) |
| Lipid lowering therapy | 3145 (92.3%) | 1851 (92.7%) | 1294 (91.7%) |
| Aspirin | 3274 (97.1%) | 1921 (97.3%) | 1353 (96.8%) |
| Beta-blockers | 3140 (95.4%) | 1863 (96.1%) | 1277 (94.4%) |
| ACE inhibitors/ARB | 2338 (72.9%) | 1366 (73.1%) | 972 (72.6%) |
|
| |||
| Participation in cardiac rehabilitation | 1731 (52.6%) | 968 (50.2%) | 763 (56.1%) |
|
| |||
| Health status at baseline | |||
|
| |||
| SF-12 Physical Component Score | 43.6 ± 12.0 | 41.7 ± 12.1 | 46.5 ± 11.2 |
|
| |||
| SF-12 Mental Component Score | 47.5 ± 12.0 | 46.8 ± 12.2 | 48.4 ± 11.6 |
|
| |||
| EQ-5D Visual Analogue Score | 65.7 ± 21.0 | 64.0 ± 21.6 | 68.1 ± 19.9 |
|
| |||
| SAQ Physical Limitation Score | 84.3 ± 23.2 | 80.7 ± 25.0 | 89.1 ± 19.3 |
|
| |||
| SAQ Angina Frequency Score | 84.6 ± 20.4 | 83.0 ± 21.6 | 86.9 ± 18.4 |
|
| |||
| SAQ Quality of Life Score | 60.3 ± 24.0 | 59.0 ± 24.6 | 62.1 ± 23.0 |
|
| |||
| SAQ Summary Score | 75.9 ± 18.5 | 73.8 ± 19.6 | 79.0 ± 16.3 |
Results shown are based on available data.
Data presented as mean (SD) [or median (25th, 75th percentiles)] for continuous variables and % for categorical variables.
All variables are from baseline at or prior to hospital discharge after hospitalization for myocardial infarction, unless otherwise specified.
ACE inhibitors, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; EQ-5D, Euro Quality of Life; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire; SF-12, The Medical Outcome Study Short From-12; TRIUMPH, Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status registry; VIRGO, Variation in Recovery Role of Gender on Outcomes of Young AMI Patients registry.